Search

Your search keyword '"Maracci, Laura"' showing total 22 results
Start Over Author "Maracci, Laura"
22 results on '"Maracci, Laura"'

1. Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey

Author

Trecarichi, Enrico Maria, Giuliano, Gabriele, Cattaneo, Chiara, Ballanti, Stelvio, Criscuolo, Marianna, Candoni, Anna, Marchesi, Francesco, Laurino, Marica, Dargenio, Michelina, Fanci, Rosa, Cefalo, Mariagiovanna, Delia, Mario, Spolzino, Angelica, Maracci, Laura, Bonuomo, Valentina, Busca, Alessandro, Principe, Maria Ilaria Del, Daffini, Rosa, Simonetti, Edoardo, Dragonetti, Giulia, Zannier, Maria Elena, Pagano, Livio, and Tumbarello, Mario

Published
2023
Full Text
View/download PDF

3. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

Author

Lessi, Federica, Criscuolo, Marianna, Farina, Francesca, Tisi, Maria Chiara, Turri, Gloria, Barone, Angelica, Spolzino, Angelica, Del Principe, Maria Ilaria, Quinto, Angela Maria, Di Blasi, Roberta, Maracci, Laura, Nabergoj, Mitja, Cambò, Benedetta, Pegoraro, Anna, Marchesi, Francesco, Pascale, Silvia, Passi, Angela, Carlisi, Melania, Polverelli, Nicola, Beggia, Barbara, Rambaldi, Benedetta, Prezioso, Lucia, Sanna, Marco, Pagano, Livio, Busca, Alessandro, Candoni, Anna, Cattaneo, Chiara, Cesaro, Simone, Fanci, Rosa, Nadali, Gianpaolo, Potenza, Leonardo, Russo, Domenico, Tumbarello, Mario, Nosari, Annamaria, and Aversa, Franco

Published
2017
Full Text
View/download PDF

9. Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study

Author

Bringhen, Sara, primary, Offidani, Massimo, additional, Musto, Pellegrino, additional, Liberati, Anna Marina, additional, Benevolo, Giulia, additional, Cascavilla, Nicola, additional, Genuardi, Mariella, additional, Gaidano, Gianluca, additional, Zamagni, Donatella, additional, Ferrando, Paola, additional, Pizzolo, Giovanni, additional, Derudas, Daniele, additional, Gambella, Manuela, additional, Dominietto, Alida, additional, Annibali, Ombretta, additional, De Sabbata, Giovanni Maria, additional, Gabbas, Attilio, additional, Musolino, Caterina, additional, Pautasso, Chiara, additional, Zambello, Renato, additional, La Nasa, Giorgio, additional, Maracci, Laura, additional, Palumbo, Antonio, additional, Hájek, Roman, additional, and Boccadoro, Mario, additional

Published
2017
Full Text
View/download PDF

10. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

Author

Pagano, Livio, Busca, Alessandro, Candoni, Anna, Cattaneo, Chiara, Cesaro, Simone, Fanci, Rosa, Nadali, Gianpaolo, Potenza, Leonardo, Russo, Domenico, Tumbarello, Mario, Nosari, Annamaria, Aversa, Franco, Lessi, Federica, Criscuolo, Marianna, Farina, Francesca, Tisi, Maria Chiara, Turri, Gloria, Barone, Angelica, Spolzino, Angelica, Del Principe, Maria Ilaria, Quinto, Angela Maria, Di Blasi, Roberta, Maracci, Laura, Nabergoj, Mitja, Cambò, Benedetta, Pegoraro, Anna, Marchesi, Francesco, Pascale, Silvia, Passi, Angela, Carlisi, Melania, Polverelli, Nicola, Beggia, Barbara, Rambaldi, Benedetta, Prezioso, Lucia, Sanna, Marco, Pagano, Livio (ORCID:0000-0001-8287-928X), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Pagano, Livio, Busca, Alessandro, Candoni, Anna, Cattaneo, Chiara, Cesaro, Simone, Fanci, Rosa, Nadali, Gianpaolo, Potenza, Leonardo, Russo, Domenico, Tumbarello, Mario, Nosari, Annamaria, Aversa, Franco, Lessi, Federica, Criscuolo, Marianna, Farina, Francesca, Tisi, Maria Chiara, Turri, Gloria, Barone, Angelica, Spolzino, Angelica, Del Principe, Maria Ilaria, Quinto, Angela Maria, Di Blasi, Roberta, Maracci, Laura, Nabergoj, Mitja, Cambò, Benedetta, Pegoraro, Anna, Marchesi, Francesco, Pascale, Silvia, Passi, Angela, Carlisi, Melania, Polverelli, Nicola, Beggia, Barbara, Rambaldi, Benedetta, Prezioso, Lucia, Sanna, Marco, Pagano, Livio (ORCID:0000-0001-8287-928X), and Tumbarello, Mario (ORCID:0000-0002-9519-8552)

Abstract

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections. Although neutropenia is common to almost all hematologic patients, other factors play a key role in specific patients, in particular in patients with AML or allogeneic HSCT recipients. Defining those patients at higher risk of IFIs may help to design the most appropriate diagnostic work-up and antifungal strategy.

Published
2017

11. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

Author

Pagano, Livio, primary, Busca, Alessandro, additional, Candoni, Anna, additional, Cattaneo, Chiara, additional, Cesaro, Simone, additional, Fanci, Rosa, additional, Nadali, Gianpaolo, additional, Potenza, Leonardo, additional, Russo, Domenico, additional, Tumbarello, Mario, additional, Nosari, Annamaria, additional, Aversa, Franco, additional, Lessi, Federica, additional, Criscuolo, Marianna, additional, Farina, Francesca, additional, Tisi, Maria Chiara, additional, Turri, Gloria, additional, Barone, Angelica, additional, Spolzino, Angelica, additional, Del Principe, Maria Ilaria, additional, Quinto, Angela Maria, additional, Di Blasi, Roberta, additional, Maracci, Laura, additional, Nabergoj, Mitja, additional, Cambò, Benedetta, additional, Pegoraro, Anna, additional, Marchesi, Francesco, additional, Pascale, Silvia, additional, Passi, Angela, additional, Carlisi, Melania, additional, Polverelli, Nicola, additional, Beggia, Barbara, additional, Rambaldi, Benedetta, additional, Prezioso, Lucia, additional, and Sanna, Marco, additional

Published
2017
Full Text
View/download PDF

13. Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey.

Author

Trecarichi, Enrico Maria, Giuliano, Gabriele, Cattaneo, Chiara, Ballanti, Stelvio, Criscuolo, Marianna, Candoni, Anna, Marchesi, Francesco, Laurino, Marica, Dargenio, Michelina, Fanci, Rosa, Cefalo, Mariagiovanna, Delia, Mario, Spolzino, Angelica, Maracci, Laura, Nadali, Gianpaolo, Busca, Alessandro, Del Principe, Maria Ilaria, Daffini, Rosa, Simonetti, Edoardo, and Dragonetti, Giulia

Subjects
ESCHERICHIA coli diseases, DISEASE risk factors, SEPTIC shock, ANTIBIOTIC prophylaxis, LIVER failure
Abstract

Bloodstream infections (BSIs) remain life-threatening complications in the clinical course of patients with haematological malignancies (HM) and Escherichia coli represent one of the most frequent cause of such infections. In this study, we aimed to describe risk factors for resistance to third generation cephalosporins and prognostic factors, including the impact of third generation cephalosporins resistance, in patients with HM and BSIs caused by E. coli. Three hundred forty-two cases of E. coli BSIs were collected during the study period (from January 2016 to December 2017). The percentage of resistance to third generation cephalosporins was 25.7%. In multivariate analysis, the variables recent endoscopic procedures, culture-positive surveillance rectal swabs for multidrug-resistant bacteria, antibiotic prophylaxis with fluoroquinolones, and prolonged neutropenia were independently associated with bloodstream infections caused by a third generation cephalosporins resistant E. coli. The overall 30-day mortality rate was 7.1%. Cox regression revealed that significant predictors of mortality were acute hepatic failure, septic shock, male sex, refractory/relapsed HM, and third generation cephalosporins resistance by E. coli isolate. In conclusion, resistance to third generation cephalosporins adversely affected the outcomes of bloodstream infections caused by E. coli in our cohort of HM patients. We also found a significant correlation between prophylaxis with fluoroquinolones and resistance to third generation cephalosporins by E. coli isolates. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

14. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

Author

Offidani, Massimo, Corvatta,Laura, Caraffa,Patrizia, Gentili,Silvia, Maracci,Laura, and Leoni,Pietro

Subjects
OncoTargets and Therapy
Abstract

Massimo Offidani,1 Laura Corvatta,2 Patrizia Caraffa,1 Silvia Gentili,1 Laura Maracci,1 Pietro Leoni1 1Hematology Department, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, 2Division of Medicine, Ospedale Stelluti Scala, Fabriano, Italy Abstract: Proteasome inhibition represents one of the more important therapeutic targets in the treatment of multiple myeloma (MM), since by suppressing nuclear factor-κB activity, which promotes myelomagenesis, it makes plasma cells susceptible to proapoptotic signals. Bortezomib, the first proteasome inhibitor approved for MM therapy, has been shown to increase response rate and improve outcome in patients with relapsed/refractory disease and in the frontline setting, particularly when combined with immunomodulatory drugs and alkylating agents. Among second-generation proteasome inhibitors, ixazomib (MLN9708) is the first oral compound to be evaluated for the treatment of MM. Ixazomib has shown improved pharmacokinetic and pharmacodynamic parameters compared with bortezomib, in addition to similar efficacy in the control of myeloma growth and prevention of bone loss. Ixazomib was found to overcome bortezomib resistance and to trigger synergistic antimyeloma activity with dexamethasone, lenalidomide, and histone deacetylase inhibitors. Phase I/II studies using ixazomib weekly or twice weekly in relapsed/refractory MM patients suggested antitumor activity of the single agent, but more promising results have been obtained with the combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed MM. Ixazomib has also been used in systemic amyloidosis as a single agent, showing important activity in this difficult-to-treat plasma-cell dyscrasia. More frequent side effects observed during administration of ixazomib were thrombocytopenia, nausea, vomiting, diarrhea, fatigue, and rash, whereas severe peripheral neuropathy was rare. Here, we review the chemical characteristics of ixazomib, as well as its mechanism of action and results from preclinical and clinical trials. Keywords: ixazomib, MLN9708, proteasome inhibitors, multiple myeloma&nbsp

Published
2014

17. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

Author

Offidani,Massimo, Corvatta,Laura, Caraffa,Patrizia, Gentili,Silvia, Maracci,Laura, Leoni,Pietro, Offidani,Massimo, Corvatta,Laura, Caraffa,Patrizia, Gentili,Silvia, Maracci,Laura, and Leoni,Pietro

Abstract

Massimo Offidani,1 Laura Corvatta,2 Patrizia Caraffa,1 Silvia Gentili,1 Laura Maracci,1 Pietro Leoni1 1Hematology Department, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, 2Division of Medicine, Ospedale Stelluti Scala, Fabriano, Italy Abstract: Proteasome inhibition represents one of the more important therapeutic targets in the treatment of multiple myeloma (MM), since by suppressing nuclear factor-κB activity, which promotes myelomagenesis, it makes plasma cells susceptible to proapoptotic signals. Bortezomib, the first proteasome inhibitor approved for MM therapy, has been shown to increase response rate and improve outcome in patients with relapsed/refractory disease and in the frontline setting, particularly when combined with immunomodulatory drugs and alkylating agents. Among second-generation proteasome inhibitors, ixazomib (MLN9708) is the first oral compound to be evaluated for the treatment of MM. Ixazomib has shown improved pharmacokinetic and pharmacodynamic parameters compared with bortezomib, in addition to similar efficacy in the control of myeloma growth and prevention of bone loss. Ixazomib was found to overcome bortezomib resistance and to trigger synergistic antimyeloma activity with dexamethasone, lenalidomide, and histone deacetylase inhibitors. Phase I/II studies using ixazomib weekly or twice weekly in relapsed/refractory MM patients suggested antitumor activity of the single agent, but more promising results have been obtained with the combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed MM. Ixazomib has also been used in systemic amyloidosis as a single agent, showing important activity in this difficult-to-treat plasma-cell dyscrasia. More frequent side effects observed during administration of ixazomib were thrombocytopenia, nausea, vomiting, diarrhea, fatigue, and rash, whereas severe peripheral neuropathy was rare. Here, we review the chemical characteristics of ixazomib, as well as its

Published
2014

18. The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy

Author

Larocca, Alessandra, primary, Bringhen, Sara, additional, Hajek, Roman, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Mina, Roberto, additional, Montefusco, Vittorio, additional, Aitoro, Gabriele, additional, Cellini, Claudia, additional, Pogliani, Enrico Maria, additional, De Paoli, Lorenzo, additional, Ruggeri, Marina, additional, Maracci, Laura, additional, Villani, Oreste, additional, Nozzoli, Chiara, additional, La Fauci, Alessia, additional, Chisini, Marta, additional, Gay, Francesca, additional, Marasca, Roberto, additional, Ballanti, Stelvio, additional, Giuliani, Nicola, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Sonneveld, Pieter, additional, and Palumbo, Antonio, additional

Published
2014
Full Text
View/download PDF

19. Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study

Author

Offidani, Massimo, primary, Maracci, Laura, additional, Corvatta, Laura, additional, Anna Marina, Liberati, additional, Ballanti, Stelvio, additional, Attolico, Imma, additional, Caraffa, Patrizia, additional, Alesiani, Francesco, additional, Caravita di Toritto, Tommaso, additional, Gentili, Silvia, additional, Tosi, Patrizia, additional, Brunori, Marino, additional, Derudas, Daniele, additional, Ledda, Antonio, additional, Gozzetti, Alessandro, additional, Cellini, Claudia, additional, Malerba, Lara, additional, Mele, Anna, additional, Felici, Stefano, additional, Galimberti, Sara, additional, Mondello, Patrizia, additional, Pulini, Stefano, additional, Coppetelli, Ugo, additional, Fraticelli, Paolo, additional, Rizzi, Rita, additional, and Leoni, Pietro, additional

Published
2014
Full Text
View/download PDF

20. Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Author

Offidani, Massimo, primary, Corvatta, Laura, additional, Maracci, Laura, additional, Liberati, Anna Marina, additional, Ballanti, Stelvio, additional, Attolico, Immacolata, additional, Caraffa, Patrizia, additional, Alesiani, Francesco, additional, Caravita di Toritto, Tommaso, additional, Gentili, Silvia, additional, Tosi, Patrizia, additional, Brunori, Marino, additional, Derudas, Daniele, additional, Ledda, Antonio, additional, Gozzetti, Alessandro, additional, Cellini, Claudia, additional, Malerba, Lara, additional, Mele, Anna, additional, Andriani, Alessandro, additional, Galimberti, Sara, additional, Mondello, Patrizia, additional, Pulini, Stefano, additional, Coppetelli, Ugo, additional, Fraticelli, Paolo, additional, Olivieri, Attilio, additional, and Leoni, Pietro, additional

Published
2013
Full Text
View/download PDF

21. Stem Cell Transplantation in Multiple Myeloma

Author

Offidani, Massimo, Gentili, Silvia, Gay, Francesca, Aghemo, Elena, Maracci, Laura, Corvatta, Laura, and Palumbo, Antonio

Abstract

High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains the standard of care for patients younger than 65 years of age with multiple myeloma (MM). However, this therapeutic approach has undergone substantial advances in this last decade, mainly due to the introduction of new drugs such as thalidomide, lenalidomide and bortezomib. These new drugs, in different combinations, have shown to significantly increase response rates after induction therapy and ASCT. Moreover, the positive results obtained with these agents in consolidation and maintenance strategies after ASCT strongly support the concept of continuous therapy, whose ultimate goal is the long-term control of the disease and the improvement of outcome. Preliminary data from studies investigating next generation proteasome inhibitors, such as carfilzomib and ixazomib, used upfront as well as at subsequent therapeutic lines, demonstrate the possibility of achieving molecular remission in most of the patients. The deeper responses obtained with new drugcombinations questioned the role of ASCT, and large, ongoing, phase 3 trials will shed light on the role and the timing of ASCT.

Published
2017
Full Text
View/download PDF

22. Current Treatment Options for Relapsed/Refractory Multiple Myeloma.

Author

Offidani, Massimo, Corvatta, Laura, Gentili, Silvia, Maracci, Laura, and Leoni, Pietro

Subjects
MULTIPLE myeloma treatment, PATIENTS, PROTEASOME inhibitors, MONOCLONAL antibodies, IMMUNOTHERAPY
Abstract

The article focuses on the treatment options for relapsed/refractory multiple myeloma (MM). Topics discussed include the criteria for choosing treatment in relapsed/refractory MM patients, the different structural classes of proteasome inhibitors (PIs), including boronates and salinosporamides, and the effects of immunomodulatory agents in relapsed/refractory MM. Also mentioned is the possible role of monoclonal antibodies (mAbs) and other immunotherapies in treating this condition.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results